|Articles|November 1, 2003

REGIMEN FOR SKIN INFECTIONS

New data suggest InterMune Inc.'s intravenous oritavancin is as effective as a regimen of vancomycin plus cephalexin in treating patients with complicated skin and skin-structure infections (CSSSI).

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME